FROG - FLORIDA RADIATION ONCOLOGY GROUP is the premier Radiation Oncology practice in America. It has grown from a single physician over 50 years ago, to our current group of 25 board certified Radiation Oncologists practicing in clinics throughout Florida.		RESEARCH In an effort to provide our patients and their families with the best possible care, all patients treated at the Florida Center for Prostate Care are closely monitored by our dedicated team and tracked in our computerized database. In addition, all seed implants are carefully analyzed for quality assurance. We continually strive to offer our patients the newest and most innovative cancer treatments available by participating in both national and regional research trials. This includes participation with: National Cancer Institute Radiation Therapy Oncology Group Eastern Co-Operative Oncology Group N.S.A.B.P. Southwest Oncology Group Numerous Pharmaceutical Companies Publications/ Presentations and Abstracts Google scholar: Jamie A. Cesaretti MD Google scholar: R Nurani MD Google scholar: Mitchell D. Terk MD Comparison of Biological Effective Dose Between Protons and Seed Implant Plus IMRT for Prostate Treatment. Brachytherapy for the treatment of prostate cancer Prostate brachytherapy preserves erectile function: Brachytherapy for prostate cancer

Long-Term Prostate Brachytherapy Outcomes With 10 Years Of Minimum Follow-up Long Term Biochemical Control And Survival In High-risk Prostate Cancer Patients Treated With Seed Implant Based Therapy Salvage Pd-103 Seed Implantation In The Treatment Of Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiation Therapy Identification Of Optimal Patients For Salvage Prostate Seed Implantation In The Treatment Of Locally Recurrent Cancer Previously Treated With External Radiation Therapy Improving the Therapeutic Ratio of Prostate Brachytherapy: Dose Escalation in I-125 Prostate Implants Radiation Dose, Not Treatment Regimen, Is the Most Significant Predictor of Biochemical Control in Patients with Intermediate Risk Prostate Cancer Use of the Surveyor Nuclease Assay to Identify Genetic Variants Predictive for the Development of Adverse Radiotherapy Effects Prognostic Significance of the 5-year PSA Value for Predicting Prostate Cancer Recurrence Following Brachytherapy Comparisons of PSA Failure Definitions Following Trimodality Therapy for Intermediate to High-Risk Prostate Cancer Dose Response Study of Pd-103 Prostate Seed Implantation Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Prostate Brachytherapy Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Prostate Brachytherapy The Effect of Family History on Outcome in Patients Treated with Low-dose Rate Brachytherapy for Clinically Localized Prostate Cancer Combined Low Dose Rate Brachytherapy and External Beam Radiotherapy Result in a Favorable Acute Urinary Symptom Profile Relative to Brachytherapy Monotherapy at the Same Biological Equivalent Dose (BED) Local Control Following Permanent Prostate Brachytherapy (PPB): Effect of High Biologic Effective Dose on Biopsy Results and Oncologic Outcomes Long term Outcomes for Patients with Gleason Scores 8-10 Prostate Cancer Treated with Combination Brachytherapy, External Beam Irradiation and Hormonal Therapy A Pretreatment PSA Level of 7 to 10 Ng/ml is an Independent Predictor of Adverse Biochemical Disease Free Survival among Low Risk Prostate Cancer Patients Treated with I-125 Brachytherapy Defining the Risk of Developing Grade 2 Proctitis Following Combined Modality Therapy using a Rectal Dose-volume Histogram Analysis and Biologic Equivalent Dose The Relationship of Erectile Dysfunction and Rectal Bleeding to Radiation Dose Following Real-time Low-dose Rate Prostate Brachytherapy Hormone use and Total Biological Equivalent Dose (BED) are Associated with Shorter PSA Doubling Times in Prostate Cancer Patients Treated with Radiotherapy who Experience a PSA Failure ATM Sequence Variants are Predictive of Adverse Radiotherapy Response Amond Patients Treated for Prostate Cancer Defining the Risk of Developing Grade 2 Proctitis Following Combined Modality Therapy using a Rectal Dose-volume Histogram Analysis and Biologic Equivalent Dose The Relationship of Erectile Dysfunction and Rectal Bleeding to Radiation Dose Following Real-time Low-dose Rate Prostate Brachytherapy Hormone use and Total Biological Equivalent Dose (BED) are Associated with Shorter PSA Doubling Times in Prostate Cancer Patients Treated with Radiotherapy who Experience a PSA Failure ATM Sequence Variants are Predictive of Adverse Radiotherapy Response Amond Patients Treated for Prostate Cancer Vardenafil Is More Efficacious Than Tadalafil For Patient's Who Requested An Alternative To Sildenafil Following Prostate Brachytherapy.

HOME | ABOUT US | PHYSICIANS | HOW YOU CAN HELP | LOCATIONS | RESOURCES | CONTACT US | PROSTATE CANCER GLOSSARY OF KEY TERMS  MAKE AN APPOINTMENT | FAQS | PROSTATE SEED IMPLANTS | PROSTATE CANCER FACTS | PROTON BEAM | PROSTATE CANCER TREATMENT OPTIONS | TERMS & USE | BOOK REQUEST | INTERNET LINKS | PDF DOWNLOADS | VIDEOS | PATIENT STORIES | NEWS | EDUCATION | RESEARCH © 2010 Florida Centers For Prostate Care | Site Map | Design: Merkley Marketing Group | Terms and Use | Privacy Policy